Bolt Biotherapeutics Announces Changes to its Board of Directors
Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company, has announced changes to its Board of Directors. Jakob Dupont, M.D., Executive Partner at Sofinnova Investments, has been appointed to the board, bringing over 20 years of experience in oncology and immuno-oncology. Concurrently, Dr. Jim Healy is stepping down as Lead Independent Director, Frank D. Lee is departing the board, and Brian O'Callaghan, CEO of Deep Genomics, will assume the role of Chair.
Dr. Dupont's extensive background includes leadership roles at Atara Biotherapeutics, Gossamer Bio, and Genentech/Roche, where he was instrumental in developing several successful cancer therapies. His appointment is expected to benefit Bolt's pipeline advancement and collaborations. The company is currently conducting a clinical trial with a first-in-class Dectin-2 agonist and has a near-clinical ISAC program targeting Claudin 18.2.
Bolt Biotherapeutics (Nasdaq: BOLT), un'azienda biofarmaceutica in fase clinica, ha annunciato delle modifiche al suo Consiglio di Amministrazione. Jakob Dupont, M.D., Partner Esecutivo presso Sofinnova Investments, è stato nominato nel consiglio, apportando oltre 20 anni di esperienza in oncologia e immuno-oncologia. Concurrentemente, Dr. Jim Healy si dimette dalla carica di Direttore Indipendente Principale, Frank D. Lee lascia il consiglio, e Brian O'Callaghan, CEO di Deep Genomics, assumerà il ruolo di Presidente.
Il vasto background del Dr. Dupont include ruoli di leadership presso Atara Biotherapeutics, Gossamer Bio e Genentech/Roche, dove è stato strumentale nello sviluppo di diverse terapie oncologiche di successo. Si prevede che la sua nomina avvantaggi l'avanzamento del pipeline di Bolt e delle collaborazioni. Attualmente, l'azienda sta conducendo un trial clinico con un agonista Dectin-2 di prima classe e ha un programma ISAC quasi clinico che punta a Claudin 18.2.
Bolt Biotherapeutics (Nasdaq: BOLT), una empresa biofarmacéutica en etapa clínica, ha anunciado cambios en su Junta Directiva. Jakob Dupont, M.D., Socio Ejecutivo en Sofinnova Investments, ha sido nombrado para la junta, aportando más de 20 años de experiencia en oncología e inmuno-oncología. Al mismo tiempo, Dr. Jim Healy renuncia como Director Independiente Principal, Frank D. Lee se retira de la junta, y Brian O'Callaghan, CEO de Deep Genomics, asumirá el rol de Presidente.
El amplio historial del Dr. Dupont incluye roles de liderazgo en Atara Biotherapeutics, Gossamer Bio y Genentech/Roche, donde fue fundamental en el desarrollo de varias terapias exitosas contra el cáncer. Se espera que su nombramiento beneficie el avance del pipeline de Bolt y sus colaboraciones. Actualmente, la empresa está llevando a cabo un ensayo clínico con un agonista Dectin-2 de primera clase y tiene un programa ISAC casi clínico dirigido a Claudin 18.2.
Bolt Biotherapeutics (Nasdaq: BOLT)는 임상 단계의 생명공학 회사로, 이사회의 변화를 발표했습니다. Jakob Dupont, M.D., Sofinnova Investments의 경영 파트너가 이사회에 선임되어 20년 이상의 종양학 및 면역 종양학 경험을 가져왔습니다. 동시에 Dr. Jim Healy는 수석 독립 이사직에서 물러나고, Frank D. Lee는 이사회를 떠나며, Brian O'Callaghan, Deep Genomics의 CEO가 의장 역할을 맡게 됩니다.
Dupont 박사는 Atara Biotherapeutics, Gossamer Bio 및 Genentech/Roche에서 리더십 역할을 맡았으며, 여러 성공적인 암 치료제 개발에 기여했습니다. 그의 임명은 Bolt의 파이프라인 발전과 협력에 도움이 될 것으로 예상됩니다. 현재 이 회사는 일류 Dectin-2 작용제와 함께 임상 시험을 진행 중이며, Claudin 18.2를 겨냥한 거의 임상 단계의 ISAC 프로그램을 운영하고 있습니다.
Bolt Biotherapeutics (Nasdaq: BOLT), une entreprise biopharmaceutique en phase clinique, a annoncé des changements au sein de son Conseil d'Administration. Jakob Dupont, M.D., Associé Exécutif chez Sofinnova Investments, a été nommé au conseil, apportant plus de 20 ans d'expérience en oncologie et en immuno-oncologie. Parallèlement, Dr. Jim Healy se retire du poste de Directeur Indépendant Principal, Frank D. Lee quitte le conseil, et Brian O'Callaghan, CEO de Deep Genomics, assumera le rôle de Président.
Le vaste parcours du Dr. Dupont inclut des postes de direction chez Atara Biotherapeutics, Gossamer Bio et Genentech/Roche, où il a joué un rôle clé dans le développement de plusieurs thérapies anticancéreuses réussies. Sa nomination devrait bénéficier à l'avancement du pipeline de Bolt et à ses collaborations. L'entreprise mène actuellement un essai clinique avec un agoniste Dectin-2 de première classe et dispose d'un programme ISAC quasiment clinique visant Claudin 18.2.
Bolt Biotherapeutics (Nasdaq: BOLT), ein biopharmazeutisches Unternehmen in der klinischen Phase, hat Änderungen im Vorstand angekündigt. Jakob Dupont, M.D., Executive Partner bei Sofinnova Investments, wurde in den Vorstand berufen und bringt über 20 Jahre Erfahrung in der Onkologie und Immunonkologie mit. Gleichzeitig tritt Dr. Jim Healy als leitender unabhängiger Direktor zurück, Frank D. Lee verlässt den Vorstand, und Brian O'Callaghan, CEO von Deep Genomics, wird den Vorsitz übernehmen.
Dr. Duponts umfangreiche Erfahrung umfasst Führungspositionen bei Atara Biotherapeutics, Gossamer Bio und Genentech/Roche, wo er maßgeblich an der Entwicklung mehrerer erfolgreicher Krebstherapien beteiligt war. Seine Ernennung wird voraussichtlich der Weiterentwicklung des Portfolios von Bolt und dessen Kooperationen zugutekommen. Das Unternehmen führt derzeit eine klinische Studie mit einem First-in-Class Dectin-2-Agonisten durch und hat ein nahezu klinisches ISAC-Programm, das auf Claudin 18.2 abzielt.
- Appointment of Jakob Dupont, M.D., with over 20 years of experience in oncology to the Board of Directors
- Ongoing clinical trial with a first-in-class Dectin-2 agonist
- Near-clinical ISAC program targeting Claudin 18.2 in development
- Company reports having sufficient resources, including cash and platform technology, to pursue its mission
- Departure of two board members, including the Lead Independent Director
REDWOOD CITY, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced the appointment of Jakob Dupont, M.D., to its Board of Directors. Dr. Dupont brings more than two decades of experience in the field of oncology and immuno-oncology. With the appointment of Dr. Dupont, Executive Partner at Sofinnova Investments, Dr. Jim Healy, M.D., Ph.D., also at Sofinnova, will be stepping down as Lead Independent Director. In addition, Frank D. Lee will be departing the Board and Brian O’Callaghan, CEO of Deep Genomics, will be assuming the role of Chair.
“Jakob has deep experience in successfully developing therapies that help cancer patients, and we are honored to have him join our Board of Directors. Jakob’s proven track record and knowledge in drug development will be beneficial as we continue to advance our pipeline and support our collaborations,” said Willie Quinn, Chief Executive Officer. “Jim and Frank have provided excellent counsel to Bolt and on behalf of the whole Board of Directors, I would like to thank them for their insights and dedication. I am also excited that Brian is stepping forward to be Chair of the board, and we all look forward to his leadership.”
Dr. Dupont is Executive Partner, Private Equity at Sofinnova Investments. Prior to joining Sofinnova, Dr. Dupont was Global Head of Research & Development and Executive Vice President at Atara Biotherapeutics, where he led the development and regulatory approval of EBVallo®. He also served as Chief Medical Officer at Gossamer Bio. Before Gossamer Bio, Dr. Dupont served as Vice President and Global Head of Breast and Gynecologic Cancer Development for Genentech/Roche, where he was responsible for the global development of Herceptin®, Perjeta®, Kadcyla®, and Tecentriq®, among others, and where he previously led the development of Avastin® for Gynecologic and Breast Cancers when starting his industry career. He serves as a Board Member for Avenzo Therapeutics, Pyxis Oncology, and Imugene, and is on the Scientific Advisory Board for Flagship Pioneering. Dr. Dupont earned his bachelor’s degree from Vassar College, his master’s degree from New York University, and his M.D. from the Joan & Sanford I. Weill Medical College of Cornell University.
“I’m pleased to join the Bolt Biotherapeutics Board of Directors,” said Jakob Dupont, M.D., Executive Partner, Private Equity, Sofinnova Investments. “The recent strategic restructuring has left Bolt in an enviable position of having an ongoing clinical trial with a first-in-class Dectin-2 agonist and a near-clinical ISAC program targeting Claudin 18.2. Additionally, Bolt has the resources, in the form of cash, platform technology, and a solid team, to pursue its mission of harnessing the power of the immune system to improve lives and eradicate cancer. I look forward to sharing my experience with the Bolt team as they advance their pipeline programs through clinical development.”
About Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. Bolt Biotherapeutics’ pipeline candidates are built on the Company’s deep expertise in myeloid biology and cancer drug development. The Company’s pipeline includes BDC-3042, a first-in-class agonist antibody that activates macrophages by targeting Dectin-2, and BDC-4182, a next-generation Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) clinical candidate targeting claudin 18.2. BDC-3042 is currently in a Phase 1 dose escalation trial that includes patients with any of seven different solid tumor types. BDC-4182 is supported by strong in vitro and in vivo data demonstrating potent anti-tumor activity, and activities are underway to support the initiation of clinical trials in 2025. Bolt Biotherapeutics is also developing additional Boltbody™ ISACs in strategic collaborations with leading biopharmaceutical companies. For more information, please visit https://www.boltbio.com/.
Forward-Looking Statements
This press release contains forward-looking statements about us and our industry that involve substantial risks and uncertainties and are based on our beliefs and assumptions and on information currently available to us. All statements other than statements of historical facts contained in this press release, including statements regarding the advancement and success of our BDC-3042 clinical trial, the potential initiation of clinical trials for BDC-4182, the anti-tumor potency, safety and tolerability, and characteristics of our product candidates, the initiation of future clinical trials, the potential value of collaborations, and the expected duration of our cash runway, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “on track,” “plan,” “potential,” “predict,” “project,” “should,” “will,” or “would,” or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements represent our current beliefs, estimates and assumptions only as of the date of this press release and information contained in this press release should not be relied upon as representing our estimates as of any subsequent date. These statements, and related risks, uncertainties, factors and assumptions, include, but are not limited to: the potential product candidates that we develop may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release; such product candidates may not be beneficial to patients or become commercialized; and our ability to maintain our current collaborations and establish further collaborations. These risks are not exhaustive. Except as required by law, we assume no obligation to update these forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. Further information on factors that could cause actual results to differ materially from the results anticipated by our forward-looking statements is included in the reports we have filed or will file with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2023. These filings, when available, are available on the investor relations section of our website at investors.boltbio.com and on the SEC’s website at www.sec.gov.
Investor Relations and Media Contact:
Matthew DeYoung
Argot Partners
(212) 600-1902
boltbio@argotpartners.com
FAQ
Who is the new board member appointed to Bolt Biotherapeutics (BOLT)?
What changes were announced in Bolt Biotherapeutics' (BOLT) Board of Directors?
What clinical programs does Bolt Biotherapeutics (BOLT) currently have?
What is Dr. Jakob Dupont's background before joining Bolt Biotherapeutics' (BOLT) board?
